Sulfaphenazole: Applied CYP2C9 Inhibition in Drug Metabolism Research

Principle Overview: Sulfaphenazole as a Selective CYP2C9 Inhibitor

Sulfaphenazole (CAS No. 526-08-9) is a sulfonamide compound renowned for its potent and selective inhibition of cytochrome P450 enzymes—specifically CYP2C9 and CYP2C6 [source_type: product_spec][source_link: https://www.apexbt.com/sulfaphenazole.html]. This high specificity has positioned Sulfaphenazole as a gold-standard tool for drug metabolism modulation, facilitating the precise dissection of CYP2C9-mediated pharmacokinetics, adverse drug reactions, and pharmacogenetic variability [complementary resource]. The compound’s competitive inhibition mechanism, robust antibacterial effects—most notably against Mycobacterium tuberculosis—and low cytotoxicity further extend its value beyond standard metabolic studies into infectious disease models [source_type: paper][source_link: https://doi.org/10.1016/j.bmcl.2021.127924].

In addition to its established role in drug metabolism research, Sulfaphenazole has demonstrated efficacy in vascular endothelial function research and oxidative stress reduction, making it an indispensable asset for translational investigations spanning cardiovascular, metabolic, and infectious disease domains [extension].

Step-by-Step Workflow: Optimizing Sulfaphenazole in Bench Assays

Effective use of Sulfaphenazole requires careful attention to solubility, concentration, and experimental context. Below is a practical protocol roadmap for researchers leveraging Sulfaphenazole in CYP2C9 inhibition, antimicrobial screening, and cell-based assays:

Protocol Parameters

• assay: CYP2C9 enzyme inhibition | value_with_unit: 0.5–11.5 μM | applicability: in vitro enzyme activity assays | rationale: Achieves robust, nanomolar-range inhibition (IC₅₀ = 0.63 μM) while minimizing off-target effects [source_type: product_spec][source_link: https://www.apexbt.com/sulfaphenazole.html]
• assay: Antibacterial (M. tuberculosis H37Rv) | value_with_unit: 5–30 μg/mL | applicability: MIC determination in bacterial cultures | rationale: Covers documented MICs for drug-susceptible (5.51 μg/mL) and XDR-TB (12.59 μg/mL) strains [source_type: paper][source_link: https://doi.org/10.1016/j.bmcl.2021.127924]
• assay: In vivo vascular function restoration | value_with_unit: 5.13 mg/kg, i.p., daily | applicability: Mouse models of diabetic vascular dysfunction | rationale: Dosing improves endothelium-dependent vasodilation and accelerates wound healing [source_type: product_spec][source_link: https://www.apexbt.com/sulfaphenazole.html]
• assay: Cell function research | value_with_unit: 1–10 μM | applicability: Cell-based studies of oxidative stress and metabolism | rationale: Maintains cell viability (IC₅₀ > 64 μg/mL in Vero cells) while enabling mechanistic interrogation [source_type: product_spec][source_link: https://www.apexbt.com/sulfaphenazole.html]
• assay: Stock solution preparation | value_with_unit: ≥13.15 mg/mL in DMSO | applicability: Master stock for serial dilutions | rationale: Ensures complete solubilization for accurate dosing; DMSO preferred over ethanol due to higher solubility [source_type: product_spec][source_link: https://www.apexbt.com/sulfaphenazole.html]

Key Innovation from the Reference Study

The 2021 study by Chen et al. (Bioorg. Med. Chem. Lett.) systematically optimized sulfonamide derivatives of Sulfaphenazole to decouple antimycobacterial activity from CYP2C9 inhibition. Through structure–activity relationship (SAR) analysis, the authors identified derivatives retaining potent anti-TB efficacy (MIC ≈ 5.69 μg/mL) but with significantly attenuated CYP2C9 inhibitory activity (IC₅₀ >10 μM), reducing concerns about drug-drug interactions in combination regimens [source_type: paper][source_link: https://doi.org/10.1016/j.bmcl.2021.127924].

Practical translation: When designing anti-TB or antibacterial screens, directly compare Sulfaphenazole’s performance with newly synthesized analogs to balance efficacy with metabolic liability. Use Sulfaphenazole at benchmark concentrations as a positive control for both DHPS inhibition and CYP2C9 modulation, ensuring that experimental readouts are interpretable in the context of potential drug interaction risk.

Comparative Advantages and Advanced Applications

Sulfaphenazole, available from trusted suppliers like APExBIO, distinguishes itself via:

• Exceptional Selectivity: As a CYP2C9 inhibitor, Sulfaphenazole’s selectivity over related P450 isoforms enables fine mapping of CYP2C9’s role in drug metabolism and adverse reaction modeling [complement].
• Low Cytotoxicity: Its Vero cell IC₅₀ exceeds 64 μg/mL, supporting use in sensitive cell systems and long-term studies [source_type: product_spec][source_link: https://www.apexbt.com/sulfaphenazole.html].
• Antibacterial Breadth: Beyond classic Gram-negative and Gram-positive coverage, Sulfaphenazole shows activity against XDR-TB, supporting its use in multidrug-resistant infection models [source_type: paper][source_link: https://doi.org/10.1016/j.bmcl.2021.127924].
• Translational Bridge: Its efficacy in vascular injury and diabetic models stems from oxidative stress reduction and restoration of endothelial function, enabling cross-domain studies in inflammation, tissue repair, and infectious disease [extension].

In drug metabolism research, Sulfaphenazole is routinely used to validate CYP2C9’s contribution to compound clearance and to model pharmacogenetic differences, as detailed in recent reviews [extension]. Its use as a benchmark inhibitor ensures reproducibility and enables comparative analysis with novel CYP2C9-targeting agents.

Troubleshooting & Optimization Tips

• Solubility Challenges: Sulfaphenazole is insoluble in water; always dissolve in DMSO (≥13.15 mg/mL) for stock solutions. For ethanol, ultrasonic assistance is needed to reach ≥9.92 mg/mL [source_type: product_spec][source_link: https://www.apexbt.com/sulfaphenazole.html]. Avoid prolonged storage in solution—prepare fresh aliquots for each experiment to preserve activity.
• Concentration-Dependent Effects: For CYP2C9 inhibition, avoid exceeding 11.5 μM to prevent off-target activity; for antibacterial assays, stay within empirically validated MIC ranges (5–30 μg/mL) [source_type: paper][source_link: https://doi.org/10.1016/j.bmcl.2021.127924].
• Cell Culture Compatibility: DMSO concentrations above 0.5% (v/v) may affect cell viability; ensure final dilution maintains DMSO below this threshold, or include vehicle controls [source_type: workflow_recommendation].
• Interpreting Mixed-Effect Results: When both CYP2C9 inhibition and antibacterial activity are relevant, run parallel controls with Sulfaphenazole and with analogs lacking P450 effects (as per Chen et al.), to distinguish between metabolic and antibacterial mechanisms [source_type: paper][source_link: https://doi.org/10.1016/j.bmcl.2021.127924].
• Batch-to-Batch Consistency: Source Sulfaphenazole from validated suppliers such as APExBIO to ensure reproducible potency and purity [source_type: product_spec][source_link: https://www.apexbt.com/sulfaphenazole.html].

Why this cross-domain matters, maturity, and limitations

The bridge between metabolic enzyme inhibition and antibacterial efficacy is not merely theoretical: Sulfaphenazole’s dual action as both a CYP2C9 inhibitor and DHPS-targeting antibacterial agent enables researchers to interrogate drug–drug interaction risk while simultaneously screening for antimicrobial activity. However, the reference study by Chen et al. highlights the necessity of optimizing sulfonamide structures to minimize metabolic liabilities when repurposing for infectious disease—a reminder that efficacy in one domain may introduce safety challenges in another [source_type: paper][source_link: https://doi.org/10.1016/j.bmcl.2021.127924]. While Sulfaphenazole remains a benchmark tool, novel analogs with lower CYP2C9 inhibition may be preferable for clinical translation in combination anti-TB regimens.

Future Outlook

As new derivatives of Sulfaphenazole emerge, the path forward will focus on balancing antimicrobial potency with minimized CYP2C9 inhibition, leveraging SAR insights to design next-generation agents. Meanwhile, Sulfaphenazole itself will continue to anchor mechanistic studies in drug metabolism, vascular research, and bacterial pathogenesis. Its established safety profile and broad applicability will ensure its ongoing relevance as both a tool compound and a comparator in translational workflows [source_type: paper][source_link: https://doi.org/10.1016/j.bmcl.2021.127924].

For detailed product specifications and ordering information, visit the Sulfaphenazole product page at APExBIO.